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Abstract: In an effort to probe the structure and function of a predicted 
mitochondrial glyoxalase 2, GLX2−1, from Arabidopsis thaliana, GLX2−1 was 
cloned, overexpressed, purified and characterized using metal analyses, 
kinetics, and UV–visible, EPR, and 1H-NMR spectroscopies. The purified 
enzyme was purple and contained substoichiometric amounts of iron and 
zinc; however, metal-binding studies reveal that GLX2−1 can bind nearly two 
equivalents of either iron or zinc and that the most stable analogue of 
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GLX2−1 is the iron-containing form. UV–visible spectra of the purified enzyme 
suggest the presence of Fe(II) in the protein, but the Fe(II) can be oxidized 
over time or by the addition of metal ions to the protein. EPR spectra revealed 
the presence of an anti-ferromagnetically-coupled Fe(III)Fe(II) centre and the 
presence of a protein-bound high-spin Fe(III) centre, perhaps as part of a 
FeZn centre. No paramagnetically shifted peaks were observed in 1H-NMR 
spectra of the GLX2−1 analogues, suggesting low amounts of the 
paramagnetic, anti-ferromagnetically coupled centre. Steady-state kinetic 
studies with several thiolester substrates indicate that GLX2−1 is not a GLX2. 
In contrast with all of the other GLX2 proteins characterized, GLX2−1 
contains an arginine in place of one of the metal-binding histidine residues at 
position 246. In order to evaluate further whether Arg246 binds metal, the 
R246L mutant was prepared. The metal binding results are very similar to 
those of native GLX2−1, suggesting that a different amino acid is recruited as 
a metal-binding ligand. These results demonstrate that Arabidopsis GLX2−1 is 
a novel member of the metallo-β-lactamase superfamily. 
Keywords: EPR, glyoxalase 2 (GLX2), iron, metallo-β-lactamase fold, zinc 
Introduction 
The GLX system consists of two enzymes, lactoylglutathione 
lyase (glyoxalase I, GLX1) and hydroxyacylglutathione hydrolase 
(glyoxalase II, GLX2), that act co-ordinately to convert a variety of α-
keto aldehydes into hydroxyacids in the presence of glutathione [1]. 
Thiohemiacetals, which are formed from the spontaneous reaction of 
α-oxo aldehydes with glutathione, are converted into S-(2-
hydroxyacyl)glutathione derivatives by GLX1. GLX2 hydrolyses S-(2-
hydroxyacyl)glutathione derivatives to regenerate glutathione and 
produce hydroxyacids. GLXI can utilize a number of α-oxo aldehydes; 
however, the primary physiological substrate of the system is thought 
to be MG (methylglyoxal), a cytotoxic and mutagenic compound that is 
formed primarily as a byproduct of carbohydrate and lipid metabolism, 
and from triose phosphates [2–4]. 
The GLX system appears to play a critical role in cellular 
detoxification processes and has received considerable attention as a 
possible antitumour and antimalarial target in animal systems [5–12]. 
Increased levels of GLX1 and GLX2 mRNA and protein have been 
detected in tumour cells, including breast carcinoma cells, while 
inhibitors of GLXI and II have been shown to inhibit the growth of 
tumour cells in vitro [4,5,8,12–19]. Plasmodium falciparum and the 
protozoan Leishmania donovani exhibit high rates of methylglyoxal 
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formation and increased levels of GLX1 activity [20]. Alterations in 
GLX activity have also been associated with several disease states. 
GLX1 and 2 can inhibit the formation of hyperglycaemia-induced 
advanced glycation end products, suggesting that these enzymes may 
have a role in diabetic microangiopathy [21]. GLX enzymes may also 
play a role in the pathogenesis of Alzheimer's disease [22,23]. Finally, 
GLX2 has been identified as a target of p63 and p73, and suggested to 
be a pro-survival factor of the p53 family of transcription factors [24]. 
GLX1, which occurs as a single isoenzyme, has been studied 
extensively in a number of systems using biochemical computational 
and X-ray crystallographic approaches [25]. In contrast, GLX2 exists 
as multiple isoenzymes and has been considerably less well 
characterized. In humans, a single gene encodes for mitochondrial and 
cytoplasmic forms of GLX2 [26]. In contrast, plants contain distinct 
genes encoding cytosolic and multiple mitochondrially localized forms 
of GLX2 [27]. Five putative GLX2 genes were identified in the 
Arabidopsis thaliana genome, including three (GLX2−1, GLX2−4 and 
GLX2−5) that were predicted to be localized in the mitochondrion 
[27]. The presence of multiple forms of GLX2 in mitochondria is 
surprising, because GLX1 and SLG (S-D-lactoylglutathione) have been 
observed only in the cytosol [1,13]. 
GLX2 enzymes belong to the metallo-β-lactamase fold 
superfamily of proteins [28,29]. Metallo-β-lactamases typically bind 
1−2 equivalents of Zn(II) [30], whereas the rubredoxin:oxygen 
oxidoreductase [31] and ZiPD (zinc phosphodiesterase) [32] families 
contain di-Fe and di-Zn centres, respectively. One version of 
Arabidopsis GLX2 (GLX2−2) was shown to bind zinc, iron and 
manganese [28,33,34], whereas GLX2−5 predominantly contains a 
Fe(III)Zn(II) centre [35]. Crystal structures of human cytoplasmic and 
plant mitochondrial GLX2 showed that the metal-binding and active 
site of GLX2 is most similar to that of metallo-β-lactamases L1 from 
Stenotrophomonas maltophilia [35–37]. One of the metal-binding sites 
(Zn1 site) consists of three conserved histidine residues, a bridging 
aspartic acid, and a bridging water/hydroxide. The second metal-
binding site (Zn2 site) has two histidines, one bridging Asp, a non-
bridging Asp, a terminally bound water and a bridging hydroxide/water 
(Figure 1). 
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Structure of mitochondrial GLX2−5 
GLX2−1, GLX2−4, and GLX2−5 share ∼80 % amino acid 
sequence identity and ∼88 % amino acid sequence similarity [27]; 
however, GLX2−1 exhibits several important differences relative to the 
other predicted mitochondrial GLX2 isoenzymes that led us to predict 
that it may in fact not be a GLX2 isoenzyme. GLX2−1 is unique among 
GLX2 enzymes in that it has an arginine instead of a histidine residue 
at position 246 of the conserved metal-binding motif (Figure 2) 
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[35,36]. In addition, five out of eight amino acids present at the active 
site of human GLX2 (Lys217, Tyr219, Tyr248, Arg325 and Lys328), which are 
involved with substrate binding and conserved in GLX2−2, GLX2−4 
and GLX2−5 [38,39], are not conserved in GLX2−1. These 
observations suggested that GLX2−1 may not contain a dinuclear 
metal centre and may not bind glutathione derivatives as substrates. 
We therefore overexpressed and purified GLX2−1 and characterized 
the protein using metal analyses and UV–visible, EPR, 1H NMR and 
EXAFS spectroscopies to understand how the amino acid differences 
affect metal binding, substrate specificity, and the structure of the 
enzyme. Our results show that GLX2−1 does in fact contain a 
dinuclear metal centre; however, it does not utlilize SLG or other GLX2 
substrates, and is therefore not a GLX2 enzyme. 
 
Figure 2: Alignment of predicted plant GLXII proteins 
The metallo-β-lactamase fold motif is shaded in grey, and substrate-binding ligands 
are indicated by triangles. Metal-binding ligands are indicated by #, * indicates the β-
lactamase fold motif. 
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Overexpression and purification of Arabidopsis GLX2−1 
PCR was conducted on A. thaliana cDNA, with the primers 
CCTCCATGGTAAAAATCGAACTGGTGC and 
GAGTCGACTCGAGCTCTAGATCTTTTTTTTTT, which generated NcoI and 
XhoI sites at the 5′ and 3′ ends of the fragment. The mature N-
terminus of the overexpressed GLX2−1 enzyme was chosen to be 
identical to that for A.thaliana GLX2−5 [35]. The GLX2−1 PCR 
fragment was cloned into pT7−7 using the NcoI and XhoI restriction 
sites, and the sequence of the resulting pGLX2−1/pT7−7 plasmid was 
confirmed by DNA sequencing. Plasmid pGLX2−1/pT7−7 was 
transformed into Escherichia coli BL21(DE3) cells and small-scale 
growth cultures were used to maximize the recovery of soluble protein 
at different temperatures (15 °C, 25 °C, 30 °C and 37 °C). 
The co-expression plasmid, pGroESL, was transformed into 
BL21(DE3) E. coli cells containing pGLX2−1/pT7−7 to assist in proper 
protein folding. The large-scale overexpression of GLX2−1 was 
performed as follows. A 10 ml overnight culture of BL21(DE3) E. coli 
containing pGroESL and pGLX2−1/pT7−7 was used to inoculate 1 litre 
of LB (Luria–Bertani) medium containing ampicillin (150 μg/ml) and 
chloramphenicol (l50 μg/ml) in the presence or absence of 250 μM 
Fe(NH4)2(SO4)2 and 250 μM Zn(SO4)2. The cells were allowed to grow 
at 37 °C with shaking until they reached an attenuance at 600 nm of 
0.6−0.8. Protein production was induced by making the cultures 0.3 
mM in IPTG (isopropyl β-d-thiogalactoside), and the cells were shaken 
at 15 °C for 24 h. The cells were collected by centrifugation (15 min at 
7000 g) and the cell pellets were stored at −80 °C until further use. 
The cell pellet was resuspended in 10 ml of 10 mM Mops, pH 
7.2, containing 0.1 mM phenylmethylsulfonyl fluoride. The cells were 
lysed by 3 passages through a French press at 16 000 lbf/in2 (1 lbf/in2 
≈ 6.9 kPa) and the cell debris was removed by centrifugation at 15 
000 g for 30 min. The cleared supernatant was dialysed against 2 
litres of 10 mM Mops, pH 7.2, overnight at 4 °C and centrifuged for 20 
min at 15 000 g to remove insoluble matter. The cleared supernatant 
was purified using FPLC with a Q-Sepharose column (1.5 × 12 cm with 
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a 25 ml bed volume) that was equilibrated with 10 mM Mops, pH 7.2. 
Bound proteins were eluted with a 0−500 mM NaCl gradient in 10 mM 
Mops, pH 7.2, at 2 ml/min. Protein purity was ascertained by 
SDS/PAGE. Fractions (8 ml) containing GLX2−1 were pooled and 
concentrated by an Amicon ultrafiltration cell equipped with a YM-10 
membrane. Enzyme concentrations were determined by measuring the 
absorbance at 280 nm and using a molar absorption coefficient of 25 
400 M−1 · cm−1, which was determined by using a Bio-Rad protein 
assay and BSA as the standard. 
Metal analyses 
The metal content of GLX2−1 samples was determined using a 
Varian-Liberty 150 ICP-AES (inductively-coupled plasma spectrometer 
with atomic emission spectroscopy detection) as described previously 
[28]. Protein samples were diluted to 10 μM with 10 mM Mops, pH 7.2. 
A calibration curve with four standards and a correlation coefficient of 
greater than 0.99 was generated using Fe, Zn and Mn reference 
solutions. The following emission wavelengths were chosen to ensure 
the lowest detection limits possible: Fe, 259.940 nm; Zn, 213.856 nm; 
and Mn, 257.610 nm. 
To evaluate metal binding to GLX2−1, a 5-fold molar excess of 
Fe(NH4)2(SO4)2, Zn(SO4)2 or Fe(NH4)2(SO4)2 plus Zn(SO4)2 were added 
directly to 10 μM apo-GLX2−1, and the mixtures were allowed to 
incubate on ice for 1 h. Unbound metal ions were removed by four 1 
litre dialysis steps against 10 mM Mops, pH 7.2, at 4 °C (12 h for each 
dialysis step). The metal content of these protein samples was 
determined using ICP-AES as described above. 
Spectroscopic studies 
UV–visible spectra were recorded using an Agilent 8453 UV-
visible spectrophotometer at 25 °C. GLX2−1 concentrations were 
approx. 1.0 mM, and the buffer was 10 mM Mops, pH 7.2. Difference 
spectra were generated using Igor Pro version 4.0.5.1 (Wavemetrics). 
EPR spectra were recorded using a Bruker E600 EleXsys 
spectrometer equipped with an Oxford Instruments ESR900 helium 
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flow cryostat and ITC503 temperature controller, and an ER4116DM 
cavity operating at 9.63 GHz in perpendicular mode. Other recording 
parameters are given in Figure 3. Quantification of signals was carried 
out by double integration of spectra recorded at non-saturating power 
(2 mW) at 12 K. A 2 mM Cu(II)-EDTA standard in Hepes buffer, pH 
7.5, recording at 60 K, 50 μW, was used. Integration limits and 
correction factors for S = ½ and S=52 signals where D is assumed to 
be small compared with temperature, were as employed elsewhere 
[39a] and described explicitly by Bou-Abdallah and Chasteen [39b] 
and references therein [39c]. Computer simulations of EPR spectra 
were carried out using XSophe (Bruker Biospin; [39d]). 
 
Figure 3 
UV–visible spectrum of 1.2 mM as-isolated GLX2−1 in 10 mM Mops, pH 7.2 
1H-NMR spectra were collected on a Bruker Avance 500 
spectrometer operating at 500.13 MHz, 298 K, magnetic field of 11.7 
T, recycle delay of 41 ms, and sweep width of 400 p.p.m. Chemical 
shifts were referenced by assigning the H2O signal a value of 4.70 
p.p.m. A modified presaturation pulse sequence (zgpr) was used to 
suppress the proton signals originating from solvent and amino acids 
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not coupled to the metal centre. The concentration of protein was 
approx. 1 mM, and 10 % 2H2O was included in samples for locking. 
Substrate specificity studies 
A series of thioesters of glutathione were used for the 
preliminary investigation of substrate specificity of as-isolated and 
Fe(II)-added GLX2−1. The substrates used were SLG (ε240 = 3100 M−1 
· cm−1), S-mandeloylglutathione (ε263 = 4200 M−1 · cm−1), S-
acetylglutathione (ε240 = 2980 M−1 · cm−1), S-acetoacetylglutathione 
(ε240 = 3400 M−1 · cm−1), S-formylglutathione (ε240 = 3300 M−1 · 
cm−1), S-glycolylglutathione (ε240 = 3260 M−1 · cm−1) and S-
lactonylglutathione (ε240 = 3310 M−1 · cm−1). With the exception of 
SLG, all substrates were synthesized as described elsewhere [40]. 
Thioester hydrolysis was monitored at 240 nm (except S-
mandeloylglutathione, 263 nm) over 60 s at 25 °C as previously 
reported [15]. The concentrations of as-isolated and Fe(II)-added 
enzyme were 10−300 μM, and substrates used were 30−600 μM. 
Overexpression and purification of the R246L mutant of 
GLX2−1 
The QuikChange® site-directed mutagenesis kit was used to 
prepare the R246L mutant of GLX2−1. PCR was conducted on plasmid 
GLX2−1/pT7−7 with the primers 
CAAATATATACTGCGGCCTTGAAAACACAGCAGGC and 
GCCTGCTGTGTTTTCAAGGCCGCAGTATATATTTG. The sequence of the 
resulting R246L-GLX2−1/pT7−7 plasmid was confirmed by DNA 
sequencing using the T7 promoter and T7 terminator primers. Plasmid 
R246L-GLX2−1/pT7−7 was transformed into E. coli BL21(DE3) cells. 
The R246L mutant was overexpressed as described above, and the 
resulting protein was insoluble. The co-expression plasmid, pGroESL, 
was transformed into BL21(DE3) E. coli cells containing R246L-
GLX2−1/pT7−7 to assist in proper protein folding. The R246L mutant 
was then overexpressed and purified as described above. 
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Overexpression and purification of A. thaliana GLX2−1 
Sequence comparisons of different GLX2 isoenzymes indicated 
that GLX2−1 has a N-terminal mitochondrial targeting sequence [27]. 
Therefore, this N-terminal leader was removed during sub-cloning to 
generate an N-terminus of MKIELVP (Figure 1), which is similar to that 
of recombinant GLX2−5, for overexpression of GLX2−1 in E. coli [35]. 
GLX2−1 could be overexpressed at high levels in E. coli BL21(DE3) 
cells; however, at temperatures > 15 °C, no soluble GLX2−1 was 
recovered. When GLX2−1 was overexpressed at 15 °C, some soluble 
protein was detected in the cleared lysates; however, the recombinant 
GLX2−1 did not bind to Q-Sepharose or SP-Sepharose columns at pH 
values ranging from 6 to 8. This result suggested that the 
overexpressed GLX2−1 was improperly folded. BL21(DE3) E. coli cells, 
containing the pGLX2−1/pT7−7 plasmid, were then transformed with 
pGroESL, and the previously mentioned overexpression/purification 
protocol was followed in an effort to produce properly folded 
recombinant GLX2−1. Overexpression of GLX2−1 in the presence of 
pGroESL at 15 °C resulted in high levels of soluble recombinant 
protein, which was purified with Q-Sepharose chromatography. The 
enzyme, which eluted from the column at 100 mM NaCl in 10 mM 
Mops, pH 7.2, was purple in colour; however, the colour faded in 7−10 
days at 4 °C. Approx. 50 mg of purified GLX2−1 per litre of culture 
was obtained using this method. The resulting enzyme was shown to 
bind substoichiometric amounts of Fe and Zn(II), ranging from 
0.1−0.5 equivalent for both metals (Table 1). The enzyme did not 
exhibit any SLG hydrolase activity. 
Table 1: Metal content of GLX2−1 analogues 
 Fe (eq) Zn(II) (eq) 
Wild-type GLX2−1 
    No added metal 0.3±0.2 0.3±0.1 
    250 μM Fe plus Zn(II) added in the medium 0.3±0.1 0.3±0.2 
    3-fold excess of Fe added after purification 1.9±0.1 0.2±0.1 
    3-fold excess of Zn(II) added after purification ∼0.1 1.6±0.2 
    3-fold excess of Fe plus Zn(II) added after purification 1.6±0.2 1.6±0.2 
GLX2−1 R246L 
    250 μM Fe plus Zn(II) added in the medium ∼0.1 0.6±0.1 
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 Fe (eq) Zn(II) (eq) 
    3-fold excess of Fe added after purification 2.4±0.5 0.5±0.2 
    3-fold excess of Zn(II) added after purification 0.1 1.4±0.2 
Metal content of recombinant GLX2−1 
The substoichiometric levels of metal suggested that the 
enzyme may still not be folding properly or may need higher relative 
metal concentrations for metal binding. Therefore GLX2−1 was 
overexpressed in LB medium containing 250 μM Fe(NH4)2(SO4)2 and 
250 μM Zn(SO4)2, conditions that had previously been shown to result 
in stoichiometric binding of Fe and Zn to GLX2−5 [35]. When GLX2−1 
was overexpressed in the presence of 250 μM Fe(II) + 250 μM Zn(II), 
the purified protein was found to contain between 0.1−0.5 equivalents 
of Fe and between 0.1−0.5 equivalents of Zn(II) (Table 1). Therefore, 
the addition of metal ions to the growth medium did not greatly affect 
the amount of metal ions bound to purified GLX2−1. This result was 
surprising, since similar studies on Arabidopsis GLX2−2 showed that 
the amounts and identity of metal ion bound to the purified enzyme 
were greatly affected by metal ion present in the growth medium 
[33,34]. 
We further investigated the ability of GLX2−1 to bind metal by 
the addition of metal to the as isolated protein. The addition of a 5-fold 
molar excess of Fe(NH4)2(SO4)2, Zn(SO4)2 or both metal ions to the 
isolated purple protein in the presence or absence of a 10-fold molar 
excess of DTT (dithiothreitol) resulted in an immediate change in 
colour to brownish-yellow followed by protein precipitation. However, 
the slow addition of a 3-fold molar excess of metal ions did not result 
in protein precipitation. After exhaustive dialysis, the resulting protein 
was shown to bind 1.8−2.1 equivalent of Fe and 0.1−0.2 equivalents 
of Zn(II), 0.1 equivalents of Fe and 1.6 equivalents of Zn(II), and 1.6 
equivalents of Fe and 1.6 equivalents of Zn(II) after addition of 
Fe(NH4)2(SO4)2, Zn(SO4)2, or both metals respectively (Table 1). The 
Zn(II)-added protein was unstable and precipitated within 1 h. None of 
the metal-loaded forms of GLX2−1 exhibited any SLG hydrolase 
activity. 
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Spectroscopic studies on GLX2−1 
We predicted that the presence of an arginine residue at 
position 246 of GLX2−1 would disrupt the GLX2 binuclear metal-
binding centre and interfere with the ability of the protein to bind two 
metal atoms. However, our observation that GLX2−1 can bind two 
equivalents of metal, if excess metal is added to the purified protein, 
suggested that either Arg246 acts as a metal-binding ligand, or more 
likely another amino acid is recruited as a ligand. Spectroscopic studies 
were conducted on GLX2−1 to probe the metal binding site of enzyme. 
The UV–visible spectrum of the as-isolated protein showed a broad 
peak with maximal absorbance at 540 nm and an absorption 
coefficient of 129 M−1 · cm−1 (Figure 3). The intensity of this peak 
suggests that it is due to a ligand field (d-d) transition of high-spin 
Fe(II) [41]. This assignment is consistent with the observed loss of 
colour of the as-isolated GLX2−1 over time and when metal ions are 
added to the as-isolated protein, since both of these scenarios would 
lead to oxidation of Fe(II) to Fe(III), which would not exhibit any spin-
allowed electronic transitions [41]. 
We next attempted to characterize the metal-binding site of 
GLX2−1 by using paramagnetic 1H-NMR spectroscopy. Despite 
considerable effort, we were unable to obtain an NMR spectrum of the 
as-isolated protein, most likely due to very small levels of 
paramagnetic centres in the as-isolated protein. We were also 
unsuccessful in obtaining a spectrum for the Fe-loaded form of 
GLX2−1. This result is consistent with the UV–visible results that 
suggest that this protein probably contains only Fe(III). The presence 
of mononuclear Fe(III) or diamagnetic Fe(III)Fe(III) would result in no 
detectable paramagnetically shifted peaks [42]. 
We further characterized the as-isolated GLX2−1 using EPR 
spectroscopy. The EPR signal from as-isolated GLX2−1 (Figure 4A) 
contained contributions from at least two separate chemical species. 
The spectrum was dominated by an intense resonance at geff ∼ 4.3 due 
to Fe(III). Other transitions that are attributed to Fe(III) were also 
observed at 750 G (75 mT; geff ∼ 5.6), 900 G (90 mT; geff ∼ 7.6), 1430 
G (143 mT; geff ∼ 4.8), 1730 G (173 mT; geff ∼ 4.0) and 1850 G (185 
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mT; geff ∼ 3.7), The 750−2000 G (75−200 mT) region of the spectrum 
could not be simulated using a single set of spin Hamiltonian 
parameters and the simple E/D-strain model in XSophe. The 
unsuccessful attempts at simulation suggested that there are two 
distinct species responsible for the multiple transitions between 750 G 
and 1850 G with strains in E/D that are relatively moderate compared 
to the large strains observed for adventitious Fe(III). The lack of 
resolved splitting of the geff = 4.3 line suggests that a third species 
may additionally contribute to the intensity at geff = 4.3. These data 
indicate the existence of at least one and more likely two sites in 
GLX2−1 that bind Fe(III) in a constrained environment, in addition to 
possible adventitious binding sites. 
 
Figure 4: EPR spectra of GLX2−1 
Trace A is the EPR spectrum of as-isolated GLX2−1. Trace B is a computer simulation 
assuming two spin-coupled iron ions in an Fe(III)Fe(II) centre. Trace C is the 
spectrum of GLX2−1 after aerobic addition of Fe(II). Trace D is an expanded view of 
Trace A and Trace E is of GLX2−1 after aerobic addition of Fe(II). Experimental 
conditions were: A, 12 K, 2 mW; C, 10 K, 1 mW; D, 12 K, 2 mW; E, 10 K, 20 mW. 
Spectra A and C are shown normalized for temperature and microwave power; spectra 
D and E are shown with arbitrary intensities. 10 G (1 mT) magnetic field modulation at 
100 kHz was employed and other parameters were chosen such that spectral 
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resolution was limited by the field modulation. The parameters used for the simulation 
of Trace B were: for Fe(III), S=52, gisotropic = 2.0, D = 2 cm−1 and E/D = 0; for Fe(II), 
S = 2, g(x,y,z) = 1.970, 2.090, 2.025, D = 15 cm−1 and E/D = 0.2; for the dinuclear 
centre, J = 43 cm−1 and an inter-iron distance, r, of 3.6 Å (0.36 nm) was assumed. It 
should be noted that (i) this is not a unique solution, and (ii) the simulation was not 
sensitive to all the parameters; in particular, the dependence on r and on which iron 
was assumed to have a rhombic zero-field splitting term was slight. 
The other feature observed in the EPR spectrum of GLX2−1 was 
a signal that exhibited geff values of 1.946, 1.844 and 1.775. In 
comparison with mitochondrial GLX2−5, that exhibits this type of 
signal [35], the high field signal from GLX2−1 can be attributed to an 
Fe(III)Fe(II) dinuclear centre. The Fe(III)Fe(II) centre could be 
simulated to very good agreement (Figure 4B) assuming such a spin-
coupled centre with reasonable spin Hamiltonian parameters 
(SFe(III)=52; SFe(II) = 2; gFe(III) = 2.0; gFe(II) > 2.0; DFe(III) = 2 cm−1; 
DFe(II) = 15 cm−1; J = 43 cm−1; the solution is not unique and detailed 
parameters are given in the legend to Figure 4). The presence of this 
feature in the spectrum supports the assignment of the lower field 
features to Fe(III) in two distinct iron-binding sites in GLX2−1. 
Upon the aerobic addition of Fe(II) to GLX2−1, the purple colour 
was lost, and this loss was concomitant with the loss of the 
Fe(II)Fe(III) EPR signal (Figure 4C). In addition, subtle changes in the 
low-field region of the spectrum were observed (Figures 4C–4E). While 
the features at 1430 G (143 mT) and 1730 G (173 mT) were 
preserved, the signals at 1430 G (143 mT) and 1850 G (185 mT) were 
broadened considerably, and changes in the 700−900 G (70−90 mT) 
region were also apparent. It is noteworthy that the loss of the 
Fe(III)Fe(II) signal was not accompanied by an increase in the spin 
density due to Fe(III). The estimated spin coupling constant for the 
Fe(III)Fe(II) centre was much higher than the Zeeman interaction, 
and a Fe(III)Fe(III) centre with comparable spin coupling would not be 
expected to exhibit an EPR signal. 
Quantitation of the EPR signals from as-isolated GLX2−1 
indicated that the Fe(III)Fe(II) signal accounted for only 25 % of the 
spin density. As suggested by the results of the aerobic addition of 
Fe(II), it is likely that the fraction of the Fe(III)Fe(II) species would be 
highly dependent on sample history, including exposure to air and 
contaminating metal ions, and it is perhaps not too surprising that 
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attempts at NMR of protons experiencing paramagnetic interactions 
with this centre were unsuccessful. 
Efforts to identify substrates of GLX2−1 
Most GLX2 enzymes exhibit a substrate preference for SLG; 
however, none of the recombinant GLX2−1 variants (Table 1) 
exhibited any detectable SLG hydrolase activity. Therefore to probe 
whether GLX2−1 is a GLX2 with different substrate specificity, activity 
assays with other thioesters of glutathione were conducted in order to 
determine if GLX2−1 has GLX activity, but exhibits a preference for 
different glutathione thio-esters. Similar to the results with SLG, the 
as-isolated purple protein and GLX2−1 containing 2 equivalents of Fe 
did not hydrolyse S-mandeloylglutathione, S-acetylglutathione, S-
acetoacetylglutathione, S-formylglutathione, S-glycolylglutathione or 
S-lactonylglutathione. Therefore GLX2−1 is not a GLX2 enzyme. 
Overexpression and purification of the R246L mutant 
GLX2−1 
Our discovery that GLX2−1 binds two equivalents of metal ions 
was unexpected, given that one of the highly conserved GLX2 metal-
binding ligands is replaced by an arginine (Arg246) in GLX2−1. Our 
observation that GLX2−1 can bind two equivalents of iron or zinc 
suggested either that Arg246 has the ability to act as a metal-binding 
ligand, or that another amino acid near the active site is recruited as a 
metal-binding ligand. 
In order to evaluate further whether the amino acid at position 
246 binds the metal, the R246L mutant was made. The rationale was 
that the replacement of arginine by leucine, which is not a metal-
binding ligand, would result in a mutant that binds only 1 equivalent of 
metal. When the R246L mutant was overexpressed at 15 °C, no 
soluble protein was detected in cleared lysates, suggesting that the 
overexpressed R246L mutant was improperly folded. However, high 
levels of soluble protein were obtained when the R246L mutant was 
expressed in BL21(DE3) E. coli cells, containing pGroESL. When the 
mutant was overexpressed in the presence of 250 μM Fe and Zn(II), 
the purified protein was shown to bind 0.1 equivalent of Fe and 0.6 ± 
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0.1 equivalent of Zn(II) (Table 1). When excess iron was added to the 
purified R246L mutant, as described for wild-type GLX2−1, the 
resulting protein bound 2.4 ± 0.5 equivalents of Fe and 0.5 ± 0.2 
equivalent of Zn(II). The Zn(II)-added analogue of R246L-GLX2−1 
bound 0.1 equivalent of Fe and 1.4 ± 0.2 equivalents of Zn(II). These 
results are very similar to those of native GLX2−1. None of these 
analogues hydrolysed SLG. These results indicate that Arg246 is not 
acting as a metal-binding ligand and that a nearby amino acid is being 
recruited as part of the metal-binding centre in GLX2−1. 
Discussion 
The metallo-β-lactamase fold consists of an αβ/βα sandwich 
motif, made up of a core unit of two β-sheets surrounded by solvent-
exposed helices [29]. Members of this superfamily contain a conserved 
HXHXD motif that has been shown to bind Zn(II), Fe and Mn. There 
are several enzymes in the metallo-β-lactamase fold family, for 
example metallo-β-lactamases, GLX2, lactonase, ROO 
(rubredoxin:oxygen oxidoreductase), arylsulfatase, phosphodiesterase 
and tRNA maturase [43]. Most of the metallo-β-lactamase superfamily 
members (metallo-β-lactamases, tRNA maturase, phosphodiesterase, 
arylsulfatase and lactonase) appear to contain dinuclear Zn(II) 
centres. On the other hand, ROO appears to contain a dinuclear iron 
centre [44]. Human GLX2 was reported to contain a dinuclear Zn(II) 
centre [36]; however, plant mitochondrial GLX2 (GLX2−5) has been 
shown to contain a FeZn centre [35], and plant cytoplasmic GLX2 can 
exist with a number of possible metal centres, including dinuclear Fe, 
FeZn, MnZn and presumably dinuclear Zn(II) [33,34]. 
Arabidopsis GLX2−1 is highly similar to GLX2−5 and is clearly a 
member of the metallo-β-lactamase fold superfamily [29]. However, 
GLX2−1 is unique in that it contains an arginine residue at position 
246, which is a metal-binding histidine in all other GLX2 enzymes [43]. 
Since arginine should be positively charged at neutral pH values, we 
hypothesized that GLX2−1 would not contain a dinuclear metal centre. 
Therefore, it was not surprising that as-isolated recombinant GLX2−1 
contained less than 1 equivalent of total metal. This form of the 
protein was purple, and, based on UV–visible studies and the molar 
absorption coefficient of the peak at 550 nm, we predict that the 
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colouration is due to ligand field transitions of Fe(II) bound to the 
protein. The Fe(II) can be oxidized to the colourless Fe(III) during 
short term storage or by the addition of metal ions. EPR studies were 
conducted to characterize further the metal-binding site in the as-
isolated protein, and the spectrum clearly shows the presence of 
protein-bound high-spin Fe(III). In addition, the spectrum showed the 
presence of small amounts, up to 25 %, of an anti-ferromagnetically 
coupled Fe(III)Fe(II) centre that has previously been observed in 
GLX2−2 and GLX2−5 [33–35] and in the purple acid phosphatases 
[45,46]. Addition of metal ions to the sample resulted in the loss of 
the Fe(III)Fe(II) signal with no concomitant increase in the Fe(III) 
signal, which suggests that the purple colouration arises from Fe(II) in 
the Fe(III)Fe(II) centre. The lack of paramagnetically shifted 1H 
resonances in the NMR spectra strongly indicates that there are low 
levels of either Fe(III)Fe(II) or mononuclear Fe(II). The protons 
coupled to Fe(III) would probably be broadened too much for 
detection. Our finding that as-isolated GLX2−1 appears to contain a 
dinuclear Fe(III)Fe(II) centre, but overall binds less than two 
equivalents of metal, may be due to the fact that the metal falls out of 
the protein during the purification process because Arg246 does not 
allow the enzyme to bind tightly to metal. Taken together, these data 
suggest that as-isolated GLX2−1 contains small amounts of a 
Fe(III)Fe(II) centre and larger amounts of FeZn [Fe(III) or Fe(II)] and 
possibly ZnZn centres. It is also possible that there are significant 
amounts of mononuclear Fe(II) or a Fe(III)Fe(III) centre in the 
protein. 
In an attempt to saturate the metal-binding site, we incubated 
the purified protein with excess Zn(II) or Fe, and, after dialysis to 
remove loosely bound or unbound metal ions, GLX2−1 was found to 
bind nearly 2 equivalents of metal. There does not appear to be 
significant discrimination in metal binding, and dinuclear Zn(II), Fe and 
FeZn centres can apparently be generated if the protein is incubated 
with Zn(II), Fe, or Fe and Zn(II). Empirically, the Zn(II)-containing 
analogues are not stable and precipitate relatively quickly once they 
are prepared, while the Fe-containing analogues are stable for long 
periods of time. It is not clear why the Zn(II)-containing forms of the 
protein are unstable. Nonetheless, the ability of GLX2−1 to bind 2 
equivalents of metal was unexpected, given that the protein has an 
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arginine residue at position 246, which is not a common metal-binding 
ligand due to its charge. 
In order to investigate further whether Arg246 binds metal, the 
R246L mutant was generated and characterized. The resulting protein 
after being loaded with Fe and/or Zn(II) exhibited metal-binding 
properties similar to those of the wild-type enzyme. The ability of the 
R246L mutant to bind 2 moles of metal was unexpected because 
leucine is not a metal-binding ligand. This result strongly suggests that 
the amino acid at position 246 is not involved in metal binding. Since 
the dinuclear metal centre is present, this result suggests that another 
active site residue is recruited to bind metal in GLX2−1. 
The results of steady-state kinetic studies with GLX2−1, using a 
number of different thiolester substrates, indicate that GLX2−1 is not a 
GLX2 enzyme. The amino acid sequences of GLX2−1 and GLX2−5 
exhibit ∼80% identity and ∼88% similarity [27]. However, five of 
seven active-site residues involved with substrate binding 
(glutathione) in GLX2−2 [39] and human GLX2 [36] are not conserved 
in GLX2−1 (Figure 2). It is possible that the different metal-containing 
analogues of GLX2−1 that we generated in this study are not the 
physiologically relevant form(s) of the enzyme, or that the absence of 
GLX2 activity could be due to improperly folded protein. However, 
previous work on GLX2−2 has shown that this enzyme can utilize a 
number of different metal centres for catalysis [33,34], and this 
scenario certainly would offer the organism (Arabidopsis in this case) 
with an evolutionary advantage, because toxins could be removed 
regardless of the metal content. The most straightforward 
interpretation of the steady-state kinetic studies is that GLX2−1 is not 
a GLX2. At this time, the function for GLX2−1 is unknown; however, 
molecular studies are being conducted in an effort to identify the 
physiological role of this protein. In addition, we are attempting to 
solve the crystal structure of the protein in the hope that the active-
site structure can offer some clue as to the natural substrate [47]. It is 
likely that GLX2−1 will represent a novel function for a metallo-β-
lactamase superfamily member [43]. 
Our previous sequence comparison study identified five genes 
that were predicted to encode for GLX2 isozymes (GLX2−1, 2−2, 2−3, 
2−4 and 2−5) in A. thaliana [27]. We have demonstrated that GLX2−2 
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and GLX2−5 are in fact GLX2 enzymes [27,28,35] and that they 
contain dinuclear metal-binding sites [34,35,48]. We recently showed 
that GLX2−3 contains a mononuclear Fe(II) site [50] and is not a 
GLX2 [49]. Moreover, this protein is probably a plant analogue of 
ethylmalonic encephalopathy protein 1 [51], which is a human protein 
potentially involved with β-oxidation of short-chain acyl-CoAs. The 
data presented herein demonstrate that GLX2−1 is also not a GLX2, 
but it contains a dinuclear metal binding site. To date, there is no 
information on the mitochondrial GLX2−4 protein, and studies are in 
progress to address whether this protein is a GLX2. 
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